2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.

Einhorn, Lawrence H; Rapoport, Bernardo; Navari, Rudolph M; Herrstedt, Jørn; Brames, Mary J

Einhorn, Lawrence H; Rapoport, Bernardo; Navari, Rudolph M; Herrstedt, Jørn; Brames, Mary J.

Affiliation

Einhorn LH; Division of Hematology-Oncology, Simon Cancer Center, Indiana University, 535 Barnhill Dr, Indianapolis, IN, 46202, USA.
Rapoport B; The Medical Oncology Centre of Rosebank, 129 Oxford Road, Saxonwold 2196, Johannesburg, South Africa. brapoport@rosebankoncology.co.za.
Navari RM; , 4518 Crown Point Lane, Mount Olive, AL, 35117, USA.
Herrstedt J; Department of Oncology, Odense University Hospital, 5000, Odense, Denmark.
Brames MJ; Division of Hematology-Oncology, Simon Cancer Center, Indiana University, 535 Barnhill Dr, Indianapolis, IN, 46202, USA.

Support Care Cancer ; 25(1): 303-308, 2017 01.

Article in En | MEDLINE | ID: mdl-27815710

Subject(s)

Antiemetics/therapeutic use; Antineoplastic Agents/adverse effects; Nausea/prevention & control; Vomiting/prevention & control; Antineoplastic Agents/administration & dosage; Consensus; Dose-Response Relationship, Drug; Humans; Induction Chemotherapy/adverse effects; Induction Chemotherapy/methods; Nausea/chemically induced; Practice Guidelines as Topic; Vomiting/chemically induced

Key words

5-HT3 receptor antagonists; Breakthrough nauseas and vomiting; CINV; High-dose chemotherapy; Multiple-day chemotherapy; NK1 receptor antagonists

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Vomiting / Antiemetics / Nausea / Antineoplastic Agents Type of study: Clinical_trials / Guideline / Prognostic_studies Limits: Humans Language: En Journal: Support Care Cancer Journal subject: NEOPLASIAS / SERVICOS DE SAUDE Year: 2017 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links